The opdualag market research report is one of a series of new reports that provides opdualag market statistics, including the opdualag industry global market size, regional shares, competitors with the opdualag market share, detailed opdualag market segments, market trends, and opportunities, and any further data you may need to thrive in the opdualag industry. This opdualag market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to rising demand for improved diagnostic solutions, growing popularity of intralesional therapy, ongoing clinical trials and regulatory approvals leading to new treatments, rising geriatric population, and increasing prevalence of melanoma. Major trends in the forecast period include the adoption of immunotherapy, combination therapies, personalized cancer treatment, the development of biosimilars, and digital tools in cancer care.
The increasing incidence of advanced melanoma is expected to drive the growth of the Opdualag market. Advanced melanoma occurs when the cancer has spread from the skin to other parts of the body, including the lymph nodes, organs, or distant tissues. This rise in advanced melanoma cases is largely influenced by factors such as increased sun exposure, genetic predispositions, and enhanced detection through screening methods. Opdualag addresses metastatic melanoma by combining nivolumab and relatlimab to strengthen the immune response, offering a targeted treatment option. For example, Cancer Research UK reported in July 2024 that the number of new melanoma skin cancer cases in the UK is anticipated to increase from around 20,800 in 2023-2025 to approximately 26,500 by 2038-2040. As such, the rising incidence of advanced melanoma is driving the growth of the Opdualag market.
The growth of the Opdualag market is also being propelled by the rise in healthcare spending. Healthcare spending refers to the total financial commitment toward medical services, supplies, research, and healthcare infrastructure. Factors such as an aging population, higher demand for medical services, technological innovations, and the escalating costs of treatments and medications contribute to the increase in healthcare expenditure. Opdualag helps manage the financial impact of advanced melanoma by providing an effective treatment that can lead to better patient outcomes and potentially lower long-term healthcare costs. According to the Centers for Medicare and Medicaid Services, US healthcare spending rose by 4.1% in 2022, reaching $4.5 trillion, compared to a 3.2% increase in 2021. This growing healthcare spending is expected to drive further growth in the Opdualag market.
A key trend in the Opdualag market is the development of dual immunotherapy treatments aimed at improving cancer treatment outcomes. Dual immunotherapy involves the use of two different immune-targeting therapies that work together to enhance the body’s immune response against cancer by targeting multiple immune checkpoints or pathways. For instance, in September 2022, Bristol Myers Squibb received European Commission approval for Opdualag, a combination of the PD-1 inhibitor nivolumab and the LAG-3-blocking antibody relatlimab. This treatment is approved for adults and adolescents aged 12 and older with unresectable or metastatic melanoma and low tumor cell PD-L1 expression. The approval was based on results from the Phase 2/3 RELATIVITY-047 trial, which showed that patients receiving Opdualag had a median progression-free survival of 10.1 months, a significant improvement over the 4.6 months achieved with nivolumab alone.
The key company operating in the opdualag market is Bristol-Myers Squibb Company.
North America was the largest region in the opdualag market in 2024. The regions covered in opdualag report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the opdualag market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Opdualag is a combination immunotherapy treatment that includes nivolumab (a PD-1 inhibitor) and relatlimab (a LAG-3 inhibitor), designed to enhance the body's immune response against cancer cells. It is used to treat advanced melanoma and other cancers by boosting immune system activity, offering a potential alternative to traditional cancer therapies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Opdualag include non-small cell lung cancer (NSCLC), melanoma, mismatch repair-deficient or microsatellite instability-high cancers, squamous cell carcinoma of the head and neck (SCCHN), renal cell carcinoma (RCC), classical Hodgkin lymphoma (cHL), and urothelial carcinoma (UC). Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer, characterized by the uncontrolled growth of abnormal cells in the lungs. Opdualag is distributed through various channels, including direct sales, online pharmacies, and wholesale distributors, and is used by multiple end users, including hospitals, oncology clinics, and pharmaceutical distributors.
The opdualag market consists of sales of inhibitors, monoclonal antibodies, vials of nivolumab, and IV infusion sets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to rising demand for improved diagnostic solutions, growing popularity of intralesional therapy, ongoing clinical trials and regulatory approvals leading to new treatments, rising geriatric population, and increasing prevalence of melanoma. Major trends in the forecast period include the adoption of immunotherapy, combination therapies, personalized cancer treatment, the development of biosimilars, and digital tools in cancer care.
The increasing incidence of advanced melanoma is expected to drive the growth of the Opdualag market. Advanced melanoma occurs when the cancer has spread from the skin to other parts of the body, including the lymph nodes, organs, or distant tissues. This rise in advanced melanoma cases is largely influenced by factors such as increased sun exposure, genetic predispositions, and enhanced detection through screening methods. Opdualag addresses metastatic melanoma by combining nivolumab and relatlimab to strengthen the immune response, offering a targeted treatment option. For example, Cancer Research UK reported in July 2024 that the number of new melanoma skin cancer cases in the UK is anticipated to increase from around 20,800 in 2023-2025 to approximately 26,500 by 2038-2040. As such, the rising incidence of advanced melanoma is driving the growth of the Opdualag market.
The growth of the Opdualag market is also being propelled by the rise in healthcare spending. Healthcare spending refers to the total financial commitment toward medical services, supplies, research, and healthcare infrastructure. Factors such as an aging population, higher demand for medical services, technological innovations, and the escalating costs of treatments and medications contribute to the increase in healthcare expenditure. Opdualag helps manage the financial impact of advanced melanoma by providing an effective treatment that can lead to better patient outcomes and potentially lower long-term healthcare costs. According to the Centers for Medicare and Medicaid Services, US healthcare spending rose by 4.1% in 2022, reaching $4.5 trillion, compared to a 3.2% increase in 2021. This growing healthcare spending is expected to drive further growth in the Opdualag market.
A key trend in the Opdualag market is the development of dual immunotherapy treatments aimed at improving cancer treatment outcomes. Dual immunotherapy involves the use of two different immune-targeting therapies that work together to enhance the body’s immune response against cancer by targeting multiple immune checkpoints or pathways. For instance, in September 2022, Bristol Myers Squibb received European Commission approval for Opdualag, a combination of the PD-1 inhibitor nivolumab and the LAG-3-blocking antibody relatlimab. This treatment is approved for adults and adolescents aged 12 and older with unresectable or metastatic melanoma and low tumor cell PD-L1 expression. The approval was based on results from the Phase 2/3 RELATIVITY-047 trial, which showed that patients receiving Opdualag had a median progression-free survival of 10.1 months, a significant improvement over the 4.6 months achieved with nivolumab alone.
The key company operating in the opdualag market is Bristol-Myers Squibb Company.
North America was the largest region in the opdualag market in 2024. The regions covered in opdualag report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the opdualag market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Opdualag is a combination immunotherapy treatment that includes nivolumab (a PD-1 inhibitor) and relatlimab (a LAG-3 inhibitor), designed to enhance the body's immune response against cancer cells. It is used to treat advanced melanoma and other cancers by boosting immune system activity, offering a potential alternative to traditional cancer therapies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Opdualag include non-small cell lung cancer (NSCLC), melanoma, mismatch repair-deficient or microsatellite instability-high cancers, squamous cell carcinoma of the head and neck (SCCHN), renal cell carcinoma (RCC), classical Hodgkin lymphoma (cHL), and urothelial carcinoma (UC). Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer, characterized by the uncontrolled growth of abnormal cells in the lungs. Opdualag is distributed through various channels, including direct sales, online pharmacies, and wholesale distributors, and is used by multiple end users, including hospitals, oncology clinics, and pharmaceutical distributors.
The opdualag market consists of sales of inhibitors, monoclonal antibodies, vials of nivolumab, and IV infusion sets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Opdualag Market Characteristics4. Opdualag Market Trends And Strategies5. Opdualag Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Opdualag Pricing Analysis & Forecasts30. Global Opdualag Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Opdualag Market32. Recent Developments In The Opdualag Market
3. Opdualag Market Biologic Drug Characteristics
6. Global Opdualag Growth Analysis And Strategic Analysis Framework
8. Opdualag Market Segmentation
9. Global Opdualag Epidemiology Of Clinical Indications
10. Opdualag Market Regional And Country Analysis
11. Asia-Pacific Opdualag Market
12. China Opdualag Market
13. India Opdualag Market
14. Japan Opdualag Market
15. Australia Opdualag Market
16. South Korea Opdualag Market
17. Western Europe Opdualag Market
18. UK Opdualag Market
19. Germany Opdualag Market
20. France Opdualag Market
21. Eastern Europe Opdualag Market
22. North America Opdualag Market
23. USA Opdualag Market
24. Canada Opdualag Market
25. South America Opdualag Market
26. Middle East Opdualag Market
27. Africa Opdualag Market
28. Opdualag Market Competitive Landscape And Company Profiles
29. Global Opdualag Market Pipeline Analysis
33. Opdualag Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Opdualag Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on opdualag market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for opdualag ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The opdualag market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Clinical Indications: Non-Small Cell Lung Cancer (NSCLC); Melanoma; Mismatched Repair Deficient Or Microsatellite Instability-High; Squamous Cell Carcinoma Of The Head And Neck (SCCHN); Renal Cell Carcinoma (RCC); Classical Hodgkin Lymphoma (cHL); Unrothelial Carcinoma (UC)2) By Distribution Channel: Direct Sales; Online Pharmacies; Wholesale Distributors
3) By End User: Hospitals; Oncology Clinics; Pharmaceutical Distributors
Key Companies Profiled: Bristol-Myers Squibb Company
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Bristol-Myers Squibb Company
